Press Enter to search · ESC to close

Macro

Fosun Pharma: Oral Alzheimer’s Drug AR1001 Misses Statistical Significance in Phase III

Fosun Pharma said global multicenter Phase III trial data for its oral investigational drug AR1001 in early Alzheimer’s disease showed a between-group difference between the treatment arm and placebo in the overall population, but the result did not reach statistical significance. The company disclosed the topline finding without providing further efficacy detail.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback